In past 2 decades, Dr. Jeng has participated in several international multi-center randomized clinical trials, mainly focus on acute stroke and stroke prevention, main trials including MATCH, PRoFESS, PERFORM, RELY, ATACH-2, EXTEND, STOP-AUST, THALES, STOP-MSU, etc. Besides, Dr. Jeng also conducted some PI-initiated multi-center clinical trials. These trials have been published in international outstanding journals, including NEJM, Lancet Neurology, BMJ, Circulation, Annals of Neurology, Neurology, JNNP, Stroke, Journal of Stroke, International Journal of Stroke, European Journal of Neurology, Scientific Reports, etc.

Dr. Lin is a professor in Department of Neurology, National Taiwan University Hospital. Her main research interests include Parkinson’s disease (PD), movement disorders, neurodegenerative disorders and young-onset Parkinson’s disease. Dr. Lin is active in many steering committees of International Movement Disorder Society. In addition to clinical studies, Dr. Lin investigated the molecular mechanisms of mutations of Parkinson’s disease or dystonia causative genes in neuronal degeneration by using cellular and animal model systems, and also involved in establishing biomarkers reflecting disease progression of Parkinson’s disease. Dr. Lin has established transgenic Drosophila and mice model of PD to investigate the molecular mechanism leading to neurodegeneration. Based on these PD models, Dr. Lin has screened a bank of FDA-approven drug library and identified Lovastatin could mitigate dopaminergic neuron degeneration. Dr. Lin then raised a principal-investigator initiated phase II, double-blind, placebo controlled clinical trial exploring the neuroprotective effects of Lovastatin in patients with early-stage and drug naive PD. The results showed a beneficial effects and contributes to the mechanism-targeted therapy in the field of PD. Dr. Lin was invited to share the result of this trial in the 13th Alzheimer's & Parkinson's Diseases Congress - AD/PD™ in Vienna, Austria in 2017. She is now a leading PI in a phase II trial for a novel 18F-PMPBB3 (APN-1607) PET imaging tracer in differentiating patients with Parkinsonism syndrome from PD. Dr. Lin is now serving as a president of Taiwan Movement Disorder Society.